Psychiatr. praxi. 2026;27(1):44-48 | DOI: 10.36290/psy.2026.010

Early dose escalation of lurasidone as part of combination pharmacotherapy in a patient with schizophrenia

MUDr. Adam Nemček, PhD.
Psychiatrické oddělení FNsP Nové Zámky, Slovenská republika

Inadequate response to initial antipsychotic therapy is relatively common in patients with schizophrenia. In case of inadequate response to initial antipsychotic treatment, it is possible to increase the dose of initial antipsychotic, replace the antipsychotic with another, or resort to a combination of antipsychotics. Insufficient response to antipsychotic treatment after two weeks is a negative predictor of response to the aforementioned treatment even in the longer term. Therefore, the period of two weeks from the start of treatment appears to be a suitable interval for assessing the effectiveness of an antipsychotic and also the time for intervention. Although clozapine is considered the gold standard in the treatment of drug-resistant schizophrenia, there are situations in clinical practice when further increasing clozapine may bring risk and combination therapy may bring benefit to the patient. With its receptor profile and minimal potential to increase weight gain and lead to deterioration of metabolic parameters, lurasidone appears to be a suitable candidate for the combination with clozapine. Knowledge of the effects of different doses of lurasidone on different symptom domains is important for making the right decision on the initial dose. Even after the initiation of combination antipsychotic treatment, it is appropriate to assess its effectiveness within two weeks of its initiation. Early increase in the dose of lurasidone in the absence of an early response led to an improvement in symptoms in patients compared with a more cautious strategy of keeping the original dose for a longer period. The presented case study illustrates the combined treatment with clozapine and lurasidone in a patient with paranoid schizophrenia using an early escalation strategy of lurasidone dose in the absence of adequate therapeutic response to initial dose after two weeks.

Keywords: polypharmacotherapy, pharmacoresistance, schizophrenia, early response to treatment.

Published: March 23, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nemček A. Early dose escalation of lurasidone as part of combination pharmacotherapy in a patient with schizophrenia. Psychiatr. praxi. 2026;27(1):44-48. doi: 10.36290/psy.2026.010.
Download citation

References

  1. Samara MT, et al. How many patients with schizophrenia do not respond to antipsychotic drugs in the short term? An analysis based on individual patient data from randomized controlled trials. Schizophrenia bulletin. 2019;45(3):639-646. Go to original source... Go to PubMed...
  2. Hatta K, Ito H. Strategies for early non-response to antipsychotic drugs in the treatment of acute-phase schizophrenia. Clinical psychopharmacology and Neuroscience. 2014;12(1):1. Go to original source... Go to PubMed...
  3. Rubio JM, et al. Early non-response to antipsychotic treatment in schizophrenia: a systematic review and meta-analysis of evidence-based management options. CNS drugs, 2023;37(6):499-512. Go to original source... Go to PubMed...
  4. Kane JM, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. Journal of clinical psychiatry. 2009;70(10):1348. Go to original source... Go to PubMed...
  5. Correll CHU, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophrenia bulletin. 2009;35(2):443-457. Go to original source... Go to PubMed...
  6. Kinon BJ, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophrenia research. 2008;102(1-3):230-240. Go to original source... Go to PubMed...
  7. Siskind D, et al. Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. The British Journal of Psychiatry. 2016;209(5):385-392. Go to original source... Go to PubMed...
  8. Williams AM, Park SH. Seizure associated with clozapine: incidence, etiology, and management. CNS drugs. 2015;29:101-111. Go to original source... Go to PubMed...
  9. Tiihonen J, et al. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA psychiatry. 2019;76(5):499-507. Go to original source... Go to PubMed...
  10. Siwek M, et al. Lurasidone Augmentation of Clozapine in Schizophrenia-Retrospective Chart Review. Brain Sciences. 2023;13(3):445. Go to original source... Go to PubMed...
  11. Jaeschke RR, et al. Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile. Pharmacological Reports. 2016;68:748-755. Go to original source... Go to PubMed...
  12. Nikiforuk A. Targeting the serotonin 5-HT 7 receptor in the search for treatments for CNS disorders: rationale and progress to date. CNS drugs. 2015;29:265-275. Go to original source... Go to PubMed...
  13. Fiorillo A, et al. Lurasidone in adolescents and adults with schizophrenia: from clinical trials to real-world clinical practice. Expert Opinion on Pharmacotherapy. 2022;23(16): 1801-1818. Go to original source... Go to PubMed...
  14. Hagi K, Tadashi N, Pikalov A. S5. Does the time of drug administration alter the adverse event risk of lurasidone? Schizophrenia Bulletin. 2020;46(Suppl 1):S31. Go to original source...
  15. Loebel A, et al. Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study. The Journal of clinical psychiatry. 2016;77(12):10934. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.